Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition-Reference-Cited by-同舟云学术

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

Published:2019-10-25 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Mao Wendy,Ghasemzadeh Ali,Freeman Zachary T.,Obradovic Aleksandar,Chaimowitz Matthew G.,Nirschl Thomas R.,McKiernan Emily,Yegnasubramanian Srinivasan,Drake Charles G.

Funder

Prostate Cancer Foundation

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0758-y.pdf

Reference51 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

2. Comiskey MC, Dallos MC, Drake CG. Immunotherapy in prostate Cancer: teaching an old dog new tricks. Curr Oncol Rep. 2018;20(9):75.

3. Venturini NJ, Drake CG. Immunotherapy for prostate Cancer. Cold Spring Harb Perspect Med. 2018;9(5):a030627.

4. Mao W, Drake CG. Immunotherapy for Prostate Cancer: An Evolving Landscape. In: Zitvogel L, Kroemer G, editors. Oncoimmunology: A Practical Guide for Cancer Immunotherapy. Cham: Springer International Publishing; 2018. p. 593–606.

5. Ghasemzadeh A, et al. New strategies in bladder Cancer: a second coming for immunotherapy. Clin Cancer Res. 2016;22(4):793–801.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis;Journal of Cancer Research and Clinical Oncology;2024-06-25

2. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

3. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

4. Modulating Treg stability to improve cancer immunotherapy;Trends in Cancer;2023-11

5. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy;BMC Medicine;2023-10-25